WILMINGTON, DE — Enovis Corporation (NYSE: ENOV) has announced the appointment of Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald will also take a seat on the company’s Board of Directors following the conclusion of the 2025 Annual Meeting of Stockholders on May 21. He succeeds current CEO Matt Trerotola, who is stepping down after a decade at the helm and has chosen not to seek re-election to the Board.
The leadership transition comes as Enovis reiterates its first-quarter 2025 financial guidance, expecting revenues between $555 million and $563 million, and adjusted EBITDA in the range of $97 million to $100 million.
Sharon Wienbar, the company’s Lead Independent Director, highlighted the thorough search process that resulted in McDonald’s selection. “The Board of Directors, with the assistance of a leading executive search firm, carefully identified, evaluated, and interviewed highly qualified candidates, and Damien stood out,” Wienbar said. She pointed to his strong leadership record, industry expertise, and alignment with Enovis’ business strategy and culture as key factors in the decision.
McDonald brings over 35 years of experience in the medical device industry. Most recently, he served as CEO of LivaNova, where he led initiatives that improved growth, profitability, and shareholder returns. His career also includes senior roles at Danaher, Zimmer, and Johnson & Johnson, where he demonstrated his ability to drive operational performance and cultivate a culture focused on innovation and patient outcomes.
Speaking about his new role, McDonald expressed enthusiasm about joining Enovis during a pivotal period. “I am honored to join the Enovis team at this exciting time in the Company’s history and to have the opportunity to lead the Company into its next phase of growth. I share the Company’s vision of developing innovative technologies to improve patient outcomes and I look forward to building upon Enovis’ strong foundation and delivering exceptional value for all of our stakeholders,” he said.
Outgoing CEO Matt Trerotola endorsed McDonald as the right choice to continue building on Enovis’ strategic momentum. “Damien has the experience, track record, and cultural fit to be a fantastic next leader of Enovis,” Trerotola stated.
Additionally, Enovis announced that Sharon Wienbar will transition to the role of independent Chair of the Board following Trerotola’s departure. Stakeholders can expect further discussion about the company’s management transition during its first-quarter 2025 earnings call, scheduled for May 8 at 8:30 a.m. ET.
With this leadership shift, Enovis signals its readiness to enter a new chapter, focusing on growth, innovation, and its commitment to improving patient outcomes globally.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.